A signature motif in transcriptional co-activators mediates binding to nuclear receptors

被引:0
|
作者
David M. Heery
Eric Kalkhoven
Susan Hoare
Malcolm G. Parker
机构
[1] Molecular Endocrinology Laboratory,
[2] Imperial Cancer Research Fund,undefined
来源
Nature | 1997年 / 387卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The binding of lipophilic hormones, retinoids and vitamins to members of the nuclear-receptor superfamily modifies the DNA-binding and transcriptional properties of these receptors, resulting in the activation or repression of target genes1,2. Ligand binding induces conformational changes in nuclear receptors and promotes their association with a diverse group of nuclear proteins, including SRC-1/p160 (3-5), TIF-2/GRIP-1 (refs 6, 7) and CBP/p300 (refs 4, 5, 8, 9) which function as co-activators of transcription, and RIP-140 (ref. 10), TIF-1 (ref. 11) and TRIP-1/SUG-1 (refs 12, 13) whose functions are unclear. Here we report that a short sequence motif LXXLL (where L is leucine and X is any amino acid) present in RIP-140, SRC-1 and CBP is necessary and sufficient to mediate the binding of these proteins to liganded nuclear receptors. We show that the ability of SRC-1 to bind the oestrogen receptor and enhance its transcriptional activity is dependent upon the integrity of the LXXLL motifs and on key hydrophobic residues in a conserved helix (helix 12) of the oestrogen receptor that are required for its ligand-induced activation function14. We propose that the LXXLL motif is a signature sequence that facilitates the interaction of different proteins with nuclear receptors, and is thus a defining feature of a new family of nuclear proteins.
引用
下载
收藏
页码:733 / 736
页数:3
相关论文
共 50 条
  • [21] Mutation analysis of transcriptional co-activators, CREB-binding protein and p300, in hematologic malignancies.
    Shigeno, K
    Yoshida, H
    Fujisawa, S
    Naito, K
    Shinjo, K
    Takeshita, A
    Ohnishi, K
    Ohno, R
    BLOOD, 2001, 98 (11) : 164B - 164B
  • [22] Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases
    Talukdar, Priyanka Dey
    Chatterji, Urmi
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [23] Transcriptional co-activators YAP/TAZ: Potential therapeutic targets for metastatic breast cancer
    Zhao, Wenxia
    Wang, Mengyan
    Cai, Meilian
    Zhang, Conghui
    Qiu, Yuhan
    Wang, Xiaowei
    Zhang, Tianshu
    Zhou, Huimin
    Wang, Junxia
    Zhao, Wuli
    Shao, Rongguang
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 133
  • [24] Bipartite functions of the CREB co-activators selectively direct alternative splicing or transcriptional activation
    Amelio, Antonio L.
    Caputi, Massimo
    Conkright, Michael D.
    EMBO JOURNAL, 2009, 28 (18): : 2733 - 2747
  • [25] Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases
    Priyanka Dey Talukdar
    Urmi Chatterji
    Signal Transduction and Targeted Therapy, 8
  • [26] Signature motif for nuclear hormone receptors coactivators.
    Cavailles, V
    M S-MEDECINE SCIENCES, 1997, 13 (10): : 1212 - 1213
  • [27] YAP/TAZ TRANSCRIPTIONAL CO-ACTIVATORS CREATE THERAPEUTIC VULNERABILITY TO VERTEPORFIN IN EGFR MUTANT GLIOBLASTOMA
    Read, Renee
    Vigneswaran, Krishanthan
    Boyd, Nathaniel
    Oh, Se-Yeong
    Lallani, Shoeb
    Boucher, Andrew
    Neill, Stewart
    Olson, Jeffrey
    NEURO-ONCOLOGY, 2020, 22 : 92 - 92
  • [28] Transcriptional Activation of Human Matrix Metalloproteinase-9 Gene Expression by Multiple Co-activators
    Zhao, Xueyan
    Benveniste, Etty N.
    JOURNAL OF MOLECULAR BIOLOGY, 2008, 383 (05) : 945 - 956
  • [29] The YAP/TAZ transcriptional co-activators have opposing effects at different stages of osteoblast differentiation
    Xiong, Jinhu
    Almeida, Maria
    O'Brien, Charles A.
    BONE, 2018, 112 : 1 - 9
  • [30] RPEL family proteins: transcriptional co-activators and mediators for actin-based structural alteration
    Tabuchi, Akiko
    SEIKAGAKU, 2006, 78 (10): : 987 - 997